Monitor for the separate special meeting proxy statement regarding the Scancell Holdings plc merger, which will contain material financial terms and voting recommendations. The annual meeting itself is routine with no expected surprises.
Price Chart
Executive Summary
Neuphoria Therapeutics filed a DEFA14A (additional definitive proxy soliciting materials) on September 18, 2026, alongside its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders scheduled for November 2, 2026. The filing explicitly states that the proxy statement does not contain information regarding the proposed merger with Scancell Holdings plc, which will be addressed at a separate special meeting. The annual meeting agenda includes election of one Class II director, ratification of Wolf & Company P.C. as auditor, and approval of adjournments if needed.
Key Financial Metrics
Key Facts
- Annual Meeting scheduled for November 2, 2026, in virtual-only format
- Record date for voting is September 10, 2026
- Proposals: elect one Class II director, ratify Wolf & Company P.C. as auditor, approve adjournments
- Proxy statement explicitly excludes the proposed Scancell Holdings plc merger, which will be voted on at a separate special meeting
- Estimated cost of proxy solicitation via Sodali & Co. is $20,000
- Proxy materials first sent to stockholders on or about September 21, 2026
Financial Impact
Estimated proxy solicitation cost of $20,000 — immaterial relative to company size
Risk Factors
- Low shareholder turnout could delay or complicate director election
- Pending Scancell merger introduces execution risk and potential shareholder dissent
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-037144 |
| Document: 0001140361-26-037144-index-headers.html | 0001140361-26-037144 |
| Document: 0001140361-26-037144-index.html | 0001140361-26-037144 |
| Document: 0001140361-26-037144.txt | 0001140361-26-037144 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $3.44 | awaiting T+60 | — | $3.39 (−1.45%) |
Oct 5, 2026 22d ago | SC 13G | $3.45 | awaiting T+60 | — | $3.39 (−1.74%) |
Sep 18, 2026 5w ago | DEFA14A | $3.71 | awaiting T+60 | — | $3.39 (−8.63%) |
Sep 18, 2026 5w ago | DEFA14A | $3.71 | awaiting T+60 | — | $3.39 (−8.63%) |
Sep 18, 2026 5w ago | DEF 14A | $3.71 | awaiting T+60 | — | $3.39 (−8.63%) |
Jun 26, 2026 17w ago | Press Release | $4.40 $3.74 | ▼ −15.11% | ▼ −19.50% | $3.39 (−22.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers